GATESHEAD HEALTH NHS FOUNDATION TRUST
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
8
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Vascular Augmentation of Late-life Unremitted Depression (VALUeD)
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2012-03-19
- Lead Sponsor
- Gateshead Health NHS Foundation Trust
- Target Recruit Count
- 80
- Registration Number
- NCT01557153
- Locations
- 🇬🇧
Clinical Ageing Research Unit, Newcastle upon Tyne, United Kingdom
News
Personalized mRNA Cancer Vaccine Shows Promise in Groundbreaking Bowel Cancer Trial
A 43-year-old bowel cancer patient became one of the first people globally to receive a personalized mRNA cancer vaccine designed to prevent cancer recurrence.
Queen Elizabeth Hospital Leads UK Recruitment in Global AstraZeneca Heart Failure Trial
Queen Elizabeth Hospital in King's Lynn has become the UK's leading recruiter in a global AstraZeneca-sponsored heart failure clinical trial, successfully enrolling five patients.
Yaqrit Secures £2.2 Million NIHR Grant for Pivotal DIALIVE Liver Support Device Trials
Yaqrit has received a £2.2 million ($2.85 million) grant from the UK's National Institute for Health and Care Research to fund pivotal trials of its DIALIVE liver support device across 13 UK centers.